All In Biotech

Drug Trial Radar · NCT03520686

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

102

Actual

Start

May 18, 2018

Primary completion

Oct 13, 2025

Study completion Oct 13, 2025

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
May 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • NAI + PembrolizumabDrug

    Nogapendekin alfa inbakicept (NAI, also known as N-803, ANKTIVA): Dose: 15 µg/kg Route: Subcutaneous (SC) Schedule: Day 1 every 3 weeks Pembrolizumab: Dose: 200 mg Route: Intravenous (IV) Schedule: Day 1 every 3 weeks

  • NAI + Nivolumab + IpilimumabDrug

    Nogapendekin alfa inbakicept (NAI): Dose: 15 µg/kg Route: SC Schedule: Days 1 and 22 every 6 weeks Nivolumab: Dose: 3 mg/kg Route: IV Schedule: Days 1, 15, and 29 every 6 weeks Ipilimumab: Dose: 1 mg/kg Route: IV Schedule: Day 1 every 6 weeks

  • NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or PaclitaxelDrug

    Induction (Cycles 1-4, q3w): Carboplatin: AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV or Paclitaxel 200 mg/m² IV (Investigator's choice), Day 1 For nab-paclitaxel only: additional 100 mg/m² IV on Days 8 and 15 Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1

  • Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAIDrug

    Induction (Cycles 1-4, q3w): Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1

  • Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAIDrug

    Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Atezolizumab 1200 mg IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1

  • Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAIDrug

    Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Paclitaxel 175 or 200 mg/m² IV (Investigator's choice), Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1

  • Carboplatin + Nab-paclitaxel + Atezolizumab + NAIDrug

    Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV on Days 1, 8, and 15 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1 Maintenance (Cycles ≥5, q3w): Atezolizumab 1200 mg IV, Day 1 Nogapendekin alfa inbakicept (NAI) 15 µg/kg SC, Day 1

  • PembrolizumabDrug

    Pembrolizumab 200 mg IV, Day 1 every 3 weeks

  • Pembrolizumab + Carboplatin + Nab-paclitaxel or PaclitaxelDrug

    Induction (Cycles 1-4, q3w): Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV or Paclitaxel 200 mg/m² IV, Day 1 For nab-paclitaxel only: additional 100 mg/m² IV on Days 8 and 15 Pembrolizumab 200 mg IV, Day 1 Maintenance (Cycles ≥5, q3w): Pembrolizumab 200 mg IV, Day 1

  • Drug: Cisplatin/Carboplatin and Pemetrexed plus PembrolizumabDrug

    Induction (Cycles 1-4, q3w): Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1 Maintenance (q3w): Pemetrexed 500 mg/m² IV, Day 1 Pembrolizumab 200 mg IV, Day 1

  • Cisplatin/Carboplatin and Pemetrexed plus AtezolizumabDrug

    Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Cisplatin 75 mg/m² IV or Carboplatin AUC 6 IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1 Maintenance (q3w): Atezolizumab 1200 mg IV, Day 1 Pemetrexed 500 mg/m² IV, Day 1

  • Carboplatin and Paclitaxel plus Atezolizumab and BevacizumabDrug

    Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Paclitaxel 175 or 200 mg/m² IV, Day 1 Maintenance (q3w): Atezolizumab 1200 mg IV, Day 1 Bevacizumab 15 mg/kg IV, Day 1

  • Carboplatin and Nab-paclitaxel plus AtezolizumabDrug

    Induction (Cycles 1-4, q3w): Atezolizumab 1200 mg IV, Day 1 Carboplatin AUC 6 IV, Day 1 Nab-paclitaxel 100 mg/m² IV on Days 1, 8, and 15 Maintenance (q3w): Atezolizumab 1200 mg IV, Day 1

  • Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelDrug

    Cycle length: 6 weeks Nogapendekin alfa inbakicept (NAI): 1.2 mg SC on Days 1, 15, and 29 of each cycle Nivolumab: 360 mg IV on Days 1 and 22 of each cycle Ipilimumab: 1 mg/kg IV on Day 1 of each cycle Carboplatin: AUC 6 IV on Days 1 and 22 of Cycle 1 only Nab-paclitaxel: 100 mg/m² IV on Days 1, 8, 15, 22, 29, and 36 of Cycle 1 only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: 24 Months
  2. Change in absolute lymphocyte count (ALC).Time frame: Significantly Higher ALC Values Over Time Between Experimental & Control Arms Through 27 Weeks

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Alaska Urological Institute - Alaska Clinical Research Center

    Anchorage, Alaska

  • Genesis Cancer Center

    Hot Springs, Arkansas

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

  • Adventist Health Glendale

    Glendale, California

  • MemorialCare Health System

    Long Beach, California

  • Adventist Health White Memorial

    Los Angeles, California

  • Hoag Memorial Hospital

    Newport Beach, California

  • Desert Hematology Oncology Medical Group

    Rancho Mirage, California

  • Memorial Healthcare

    Hollywood, Florida

  • Baptist Health South Florida - Miami Cancer Institute

    Miami, Florida

  • Healthcare Research Network

    Tinley Park, Illinois

  • Baptist Health - Lexington

    Lexington, Kentucky

  • Baptist Health Louisville

    Louisville, Kentucky

  • Karmanos Cancer Center

    Detroit, Michigan

  • Mercy Research Joplin

    Joplin, Missouri

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • Astera Cancer Care

    East Brunswick, New Jersey

  • University of Rochester

    Rochester, New York

  • Stony Brooke Medicine

    Stony Brook, New York

  • Mercy Research Oklahoma City

    Oklahoma City, Oklahoma

  • LeHigh Valley

    Allentown, Pennsylvania

  • Gettysburg Cancer Center

    Gettysburg, Pennsylvania

  • Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC)

    Charleston, South Carolina

  • Saint Francis Cancer Center/Bon Secours St. Francis Health System

    Greenville, South Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Baptist Cancer Center

    Memphis, Tennessee

  • Texas Oncology-Austin

    Austin, Texas

  • Texas Oncology-Bedford

    Bedford, Texas

  • Oncology Consultants, PA

    Houston, Texas

  • Bon Secours Richmond

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.